CLBS - Caladrius Biosciences Stock Trading

Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and ind...

BASKING RIDGE, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disea...

Approval received from the Japan Patent Office to use HONEDRA® as brand name for CLBS12 in Critical Limb Ischemia and Buerger’s Disease Intellectual property provides additional coverage of CD34+ cell technology in Japan BASKING RIDGE, N.J., Sept. 09, 2020 (GLOBE NEWSWI...